




Supplementary Figure 1. PAG protein expression in the top 10 highest expressing tissues¹⁴.




Supplementary Figure 2. Jurkat cells expressing PAG-GFP were stimulated with anti-CD3 alone or with PDL1 or PDL2. PAG-GFP was enriched by immunoprecipitation of the lysates and phosphotyrosine was detected by immunoblot. Representative blot of three independent experiments is shown.



Supplementary Figure 3. **a.** Jurkat cells expressing either a non-targeting shRNA (shControl) or a PAG targeting shRNA (shPAG) were lysed and run on a western blot. Immunoblot shows PAG and actin protein levels. Representative blot is shown. **b.** Jurkat cells expressing sh PAG were transfected with wild type full length PAG or phosphodeficient versions and GFP expression was quantified by flow cytometry.




Supplementary Figure 4. **a.** ELISA of secreted IL-2. Jurkat cells expressing sh Control or sh PAG were stimulated for 24 hours before supernatants were collected. Bars represent mean \pm SEM of three independent experiments. **b - e.** Representative western blots of primary T cells (b, c) and Jurkat cells (d, e) expressing si/sh control or si/sh PAG and rescue transfections with various versions of PAG into shPAG expressing Jurkat cells as indicated. **d.** Table summarizing the contributions of phosphotyrosines 181, 317, and 417 to the assessed T cell functions and PD-1 signaling.




Supplementary Figure 5. a. and b. ELISA of secreted IL-2 (a) and IFN γ (b) in the supernatants of primary human CD3 $^{+}$ T cells collected 48 hours following stimulation by magnetic beads. T cells either expressed a non-targeting siRNA (control) or PAG targeting siRNA pool (siPAG). **c and d.** Phosphorylated ERK (c) and phosphorylated SRC (d) were detected by western blot of human CD3 $^{+}$ T cell lysates 5 minutes after stimulation by magnetic beads. Fold change is calculated relative to anti-CD3 stimulation (c) or unstimulated (d). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns not significant.


a




b




c



d



e




f

Assay	WT	Y181	Y317	Y417
IL-2	+	+	++	0
Adhesion	++	0	++	0
CD69	++	++	++	++
pERK	+	0	0	0
pSRC	++	+	++	0

○ no contribution, + some contribution, ++ necessary role

Supplementary Figure 6. a. ELISA of secreted IL-2 in the supernatants of Jurkat cells collected 24 hours following stimulation by magnetic beads. Jurkat T cells either expressed a non-targeting shRNA (control) or PAG targeting shRNA (shPAG). For rescue transfections, shPAG Jurkats were transiently transfected with full length, wild type PAG (PAG FL) or with phosphodeficient mutants (Y181A, Y317A, Y417A). b. Adhesion assay of Jurkat cells to fibronectin following stimulation for 15 minutes. The number of adherent cells remaining, expressed as a percentage of the total number of labeled cells, was determined with a fluorescent plate reader. PAG knockdown and rescue transfections as in (A). c. Percentage of Jurkat cells expressing CD69 on the surface following 24 hour stimulation, measured by flow cytometry. PAG knockdown and rescue transfections as in (A). d and e. Phosphorylated ERK (D) and phosphorylated SRC (E) were detected by western blot of Jurkat lysates 5 minutes after stimulation by magnetic beads. PAG knockdown and rescue transfections as in (A). % inhibition is calculated by $100 - \text{CD3+PDL2 + CD3} * 100$. Bars represent the mean \pm SEM of three independent experiments. f. Table summarizing the contribution of each phosphotyrosine position to individual T cell functions assayed. * $p<0.05$; ** $p<0.01$; *** $p<0.001$; **** $p<0.0001$; ns not significant.



Supplementary Figure 7. Human naïve ($CD8^+CCR7^+CD62L^+$) and effector ($CD8^+CCR7^-CD62L^-$) T cells were stained with intracellular anti-PAG antibody and analyzed by flow cytometry. MFI - median fluorescent intensity.

Supplementary Table 1. IL-2 ELISA

Primary human T cells	Unstimulated			aCD3		aCD3+PDL2			
Control	20	25	0	661	640	655	201	230	227
si PAG	20	30	32	553	578	610	510	619	569
Jurkat cells	Unstimulated			aCD3		aCD3+PDL2			
Control	20	5	23	805	946	902	289	410	422
sh PAG	35	22	32	871	953	944	731	748	741
PAG FL	25	23	23	754	835	810	411	457	482
PAG Y181A	19	27	15	750	848	821	691	710	688
PAG Y317A	12	14	27	737.8349	790	780	688	756	702
PAG Y417A	33	18	29	777	810	838	440	435	398

Supplementary Table 2. IFNg ELISA

	Unstimulated			aCD3			aCD3+PDL2		
Control	27	71	46	1298	1301	1514	750	1050	920
si PAG	154	30	36	1650	1453	1404	1400	1000	1500

Supplementary Table 3. Percent inhibition of CD69 expression

	Unstimulated			aCD3			aCD3+PDL2		
Control	3	3	0	51	59	54	30	33	32
sh PAG	3	4	5	54	62	67	66	69	71
PAG FL	7	6	6	49	57	53	32	35	30
PAG Y181A	8	6	2	51	45	50	56	45	47
PAG Y317A	7	6	11	52	56	54	47	49	55
PAG Y417A	6	7	10	27	35	32	31	39	38

Supplementary Table 4. Percent inhibition of adhesion

	Unstimulated			aCD3		aCD3+PDL2		
Control	10	14	11	35	37	34	17	18
sh PAG	14	18	12	28	32	33	32	37
PAG FL	8	10	11	30	38	34	15	17
PAG Y181A	9	13	7	32	27	31	22	17
PAG Y317A	12	16	14	31	36	34	30	33
PAG Y417A	8	13	17	37	29	33	18	17

Supplementary Table 5. MC38 Tumor Measurements

Supplementary Table 6. B16F10 Tumor Measurements

Days	WT						WT + Anti-PD-1					
1	0						0					
2	0						0					
3	0						0					
4	0						0					
5	0						0					
6	0						0					
7	0						0					
8	62.5	72	108	75	43		42	68	51			
9	95	100	108	126	97		107	128	97			
10	110	133	116	140	108		115	108	124			
11	133	200	143	276	238		203	155	173			
12	158,4375	158	166	408	386,334		239,0625	288	340			
13	251	178	207	455	420	61.3	48.4	48.8	328	352	397	67.6
14	354	301	360	573	298				269	494	448	
15	465,75	710	698	606	564,9188				524	627	521	
16	769	993	1097	725	615				624	757	674	
17	1102	1205	1108	847	798	171.5	162	486	796	827	973	288
18	1547	1403	1850	1350	1220				1187	1080	1280	
19	1688	1620	2017	1505	1521	744.2	635	726	1071	1231	1533	299.2
20	1861	2017	2215	2403	2101				1374	1775	1895	
21	2043	2215	2043	1992	1700	4700.4	2070.2	1454	1775	1895	1400.6	2000.6

Days	PAG KO						PAG KO + Anti-PD-1					
	0	1	2	3	4	5	0	1	2	3	4	5
1	0						0					
2	0						0					
3	0						0					
4	0						0					
5	0						0					
6	0						0					
7	0						0					
8	154.791	125	117	108	78		41	37	66			
9	160	140	170	127	64		56	56	75			
10	165	148	199	150	76		73	112	101			
11	170	148	213	176	98		90	173	144			
12	179.5625	91	218	253.6285	110.808		141	250	204			
13	202	153	287	295	186	15.4	76.3	35.3	172	246.63	119.88	30.4
14	240	206	310	316	263		223	212.64	193.98			
15	268	179.5625	378.895	324	313.8268		270	249.77	254			
16	351	303	420	441	501		274	265	285			
17	527	451	556	600	681	64	484.3	766.1	184	301	341	395.1
18	563	433	725	633	723		453	447	305			
19	750	842	831	1046	1193	136.1	465.8	1023.4	600	463	337	885.6
20	1090	1210	1256	1330	1644		762	952	631			
21	1882	1403	1648	1425	1962	727.4	729.4	1502.3	652	1208	903	1281.8
22										1964.9	1440.3	

Supplementary Table 7. Adoptive Cell Transfer Tumor Measurements